Latest News - McKesson
Top Corporates Hub
McKesson
Cycle Pharmaceuticals Launches Its First Oncology Product, PHYRAGO™ (dasatinib) Tablets, in the US
16.10.2025 13:00
DETROIT, October 16, 2025--Cycle Pharmaceuticals announces the launch of PHYRAGO, its first oncology product in the US. PHYRAGO is launched in partnership with Handa Therapeutics, LLC, and will be exclusively available through specialty pharmacy Onco360® with a specialty distribution network from McKesson, Cencora, and Cardinal Health.
The Zacks Analyst Blog Highlights UBS, Newmont, McKesson and The Cato
16.10.2025 07:59
Zacks spotlights UBS, Newmont, McKesson, and Cato, four companies showing strong performance across finance, gold mining, healthcare distribution, and retail.
McKesson Valuation in Focus After Record Five Year Share Price Surge
16.10.2025 01:07
If you’re eyeing McKesson’s stock and wondering whether now is the right time to buy, hold, or cash in, you’re not alone. The company has been on quite a ride, and there’s plenty of chatter about its long-term value. In just the past week, McKesson’s price has climbed 4.8%, and in the last month it’s surged by a compelling 12.7%. Looking further back, the returns are even more impressive: 39.9% year-to-date, 55.7% over the last year, and a remarkable 435.3% over the past five years. Those...
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity
11.10.2025 02:08
McKesson (MCK) is a 'Buy' with high-growth potential in healthcare services. Learn key risks and outlook for stock appreciation by FY2030.
How Analysts See McKesson's Story Changing After New Targets and Upbeat Investor Day
09.10.2025 02:14
McKesson's fair value estimate has been raised from $793.21 to $829.57, driven by an improved outlook from analysts following the company's latest investor day. This adjustment reflects renewed optimism in McKesson's ability to deliver on its strategic initiatives and long-term growth plans, particularly in expanding its specialty portfolios. Stay tuned to find out how investors can continue tracking shifts in McKesson's narrative as analyst perspectives evolve. What Wall Street Has Been...
McKesson Bets on Oncology, Biopharma as It Streamlines Portfolio
08.10.2025 15:48
MCK is transforming from a traditional distributor into a specialty-driven healthcare solutions leader, focusing on oncology, biopharma services and automation while preparing to separate its Medical-Surgical unit.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
29.09.2025 13:40
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
26.09.2025 13:50
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
26.09.2025 12:30
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
McKesson raises profit guidance and long-term growth targets at Investor Day
23.09.2025 14:16
Investing.com -- McKesson lifted its earnings outlook and set higher long-term growth targets as the company’s leadership outlined strategic priorities ahead of its 2025 Investor Day on Tuesday.
McKesson lifts annual profit forecast on plans to focus on high-margin businesses
23.09.2025 14:05
(Reuters) -McKesson on Tuesday raised its profit forecast, as the U.S. drug distributor aims to focus on high-margin businesses such as cancer medicines to boost growth. The Texas-based firm now expects adjusted earnings to range between $38.05 and $38.55 per share for fiscal 2026, up from its previous forecast of $37.10 to $37.90. It also lifted its long-term adjusted earnings growth target to 13% to 16%, from a prior range of 12% to 14%.
McKesson Corporation (MCK) Analyst/Investor Day - Slideshow
23.09.2025 13:33
2025-09-23. The following slide deck was published by McKesson Corporation in conjunction with this event.
McKesson Lifts Annual Forecast, Targeting Platforms Growth
23.09.2025 12:52
McKesson updated its targets for fiscal 2026 and beyond as the diversified healthcare services company continues to advance its growth strategy.
McKesson Corporation Highlights Strategic Growth Strategies and Unveils Updated Long-term Financial Targets at Investor Day
23.09.2025 12:00
IRVING, Texas, September 23, 2025--McKesson Corporation (NYSE: MCK) will host its 2025 Investor Day today, beginning at 9:30 AM ET. During the event, executive leadership will discuss the company’s multi-year strategic priorities, growth strategies, and long-term business outlook.
McKesson Corporation (MCK): A Bull Case Theory
19.09.2025 18:30
We came across a bullish thesis on McKesson Corporation on Value investing subreddit by entropybender. In this article, we will summarize the bulls’ thesis on MCK. McKesson Corporation’s share was trading at $711.42 as of September 12th. MCK’s trailing and forward P/E were 28.49 and 18.94 respectively according to Yahoo Finance. McKesson Corporation (MCK) is resuming its […]
McKesson Announces New Organizational Structure
18.09.2025 13:00
IRVING, Texas, September 18, 2025--McKesson Corporation (NYSE: MCK) today announced changes to its reportable segments and organizational structure, effective in the second quarter of fiscal year 2026. The new reporting structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders.
USAntibiotics Working with Walmart and McKesson to Support U.S. Manufacturing of Amoxicillin
08.09.2025 14:00
BRISTOL, Tenn., September 08, 2025--USAntibiotics, the nation’s lone remaining manufacturer of amoxicillin and amoxicillin clavulanate, today announced a new collaboration with Walmart and McKesson through their joint venture partner ClarusONE Sourcing Services to provide domestically manufactured antibiotics made by USAntibiotics in the United States for millions of patients nationwide.
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?
27.08.2025 13:00
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.